Sangamo BioSciences | SGMO - Przychody Ze Sprzedaży





Obroty Zmiana Data
Alaunos Therapeutics USD 2K 2K 2025-03
Alnylam Pharmaceuticals USD 1.29B 120M 2026-06
Alterity Therapeutics Limited AUD 596.04K 584.66K 2025-12
Amgen USD 10.1B 1.48B 2026-06
Bayer EUR 10.87B 2.54B 2026-06
BioCryst Pharmaceuticals USD 218.25M 188.3M 2026-06
Biogen USD 2.74B 490M 2026-06
BioMarin Pharmaceutical USD 990M 224M 2026-06
Cipla INR 71.19B 5.78B 2026-06
Clal Biotechnology ILS 3.41M 2M 2022-12
Compugen USD 6.35M 60.98M 2026-03
CSL USD 8.33B 4.79B 2025-12
Gilead Sciences USD 7.8B 800M 2026-06
GlaxoSmithKline GBP 8.41B 781M 2026-06
Grifols EUR 2B 306.7M 2026-03
Ionis Pharmaceuticals USD 268M 22M 2026-06
J&J USD 25.31B 1.21B 2026-06
Karyopharm Therapeutics USD 35.07M 987K 2026-03
Merck USD 16.6B 310M 2026-06
Novartis USD 14.41B 1.3B 2026-06
Pfizer USD 15.03B 530M 2026-06
Roche Holding CHF 30.36B 14.71B 2026-06
Sangamo BioSciences USD 356K 125K 2024-06
Sanofi EUR 11.95B 710M 2026-06
Sarepta Therapeutics USD 401.3M 329.5M 2026-06
Tectonic Therapeutic USD 0 0 2024-12
Ultragenyx Pharmaceutical USD 214M 78M 2026-06
Vertex Pharmaceuticals USD 3.33B 340M 2026-06